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Summary 
The high-output pathway of nitric oxide production helps protect mice from infection by sev- 
eral pathogens, including Mycobacterium  tuberculosis. However, based on studies of cells cultured 
from blood, it is controversial whether human mononuclear phagocytes can express the corre- 
sponding inducible nitric oxide synthase (iNOS; NOS2). The present study examined alveolar 
macrophages fixed directly after bronchopulmonary lavage. An  average of 65%  of the  mac- 
rophages from 11  of 11  patients with untreated,  culture-positive pulmonary tuberculosis re- 
acted with an antibody documented herein to be monospecific for human NOS2.  In contrast, 
a mean of 10% ofbronchoalveolar lavage cells were positive from each of five clinically normal 
subjects. Tuberculosis patients' macrophages displayed diaphorase activity in the same propor- 
tion that they stained for NOS2, under assay conditions wherein the diaphorase reaction was 
strictly  dependent  on  NOS2  expression.  Bronchoalveolar  lavage  specimens  also  contained 
NOS2 mRNA. Thus, macrophages in the lungs of people with clinically active Mycobacterium 
tuberculosis infection often express catalytically competent NOS2. 
A 
third  of the  world's human population is thought  to 
be infected with Mycobacterium  tuberculosis (1). Though 
the vast majority of individuals hold the organism in check, 
more than 2.5 million a year fail to do so. As a result, tu- 
berculosis may be the world's leading cause of death from 
bacterial infection  (1).  It is not known how human mac- 
rophages normally suppress the proliferation of this faculta- 
tive intracellular  pathogen  nor how  the  bacterium some- 
times gains the upper hand. 
The inducible  isoform of nitric  oxide  synthase  (iNOS, 
NOS2) 1 contributes to the control of viral, bacterial, proto- 
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zoal, fungal, and helminthic infections in mice (reviewed in 
references 2 and 3). This is evident from coordinate expres- 
sion of NOS2 and anti-infectious activity; exacerbation of 
infection in vitro and in vivo by administration ofNOS in- 
hibitors; conferral of anti-infectious activity upon transfec- 
tion with NOS2 cDNA or exposure to NO-generating or- 
ganochemicals; and enhanced vulnerability to infection in 
mice rendered genetically deficient in NOS2 (4, 5). By the 
first three  criteria,  control  of experimental tuberculosis in 
mice  is  NO-dependent  (6-9).  Moreover,  mice  rendered 
genetically deficient in interferon-~/  (10),  its receptor (11), 
or interferon regulatory factor-1  (12)  are all disadvantaged 
with respect to expression of NOS2,  and all  three  mouse 
strains sustain rapid mycobacterial proliferation. 
However, the ability of human mononuclear phagocytes 
to express NOS2 is contested (13-15).  Denis obtained the 
first positive evidence: nitrite in the medium of cytokine- 
treated,  mycobacteria-infected,  monocyte-derived  macro- 
phages  (16).  Support followed from at least  16  additional 
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and detection (17-32). Nonetheless, comparable results have 
eluded many other investigators (e.g., 33-37), some of whom 
dismiss the  evidence that human  mononuclear phagocytes 
can express NOS2  at all (14)  or at a level consonant with 
host defense (38). 
One  interpretation of this controversy is that  unidenti- 
fied variables may restrict the consistency with which hu- 
man monocytes or macrophages can be induced to express 
NOS2  in vitro.  Such  suppressive influences may not per- 
tain in vivo. On this premise, we examined pulmonary al- 
veolar macrophages fixed immediately after collection from 
patients  with  tuberculosis.  Since  monocytes  can  express 
NOS2 mtLNA without detectable NOS2 protein (25), we 
centered the study on the characterization of an antibody-- 
apparently the first such reagent--with which expression of 
human  NOS2  protein  could  be  demonstrated  unequivo- 
cally. The results document the frequent expression of cat- 
alytically competent NOS2 in human macrophages from a 
site of infection. 
Materials  and Methods 
Antibody.  A  peptide  (Cys-Arg-Nle-Orn-Ser-Leu-Glu-Met- 
Ser-Ala-Leu) was synthesized to correspond to the 7 COOH-ter- 
minal residues of human  NOS2  (underlined)  plus 4  additional 
residues  to  improve  solubility, linkage  and  quantitation.  This 
peptide was coupled to thyroglobulin as described (39).  IgG was 
purified from serum of a normal rabbit on recombinant staphylo- 
coccal protein A columns (Pierce Chemicals, R.ockford, IL). The 
same  rabbit was  then  repeatedly immunized  with  the  peptide 
conjugate,  initially in  Freund's complete adjuvant  and then  in 
Freund's incomplete adjuvant. IgG was purified from the antisera, 
collectively termed NO53.  F(ab')2 fragments were prepared by 
digestion with immobilized pepsin (Pierce) and purified as above. 
The  synthetic  peptide NO54  (Tyr-Arg-Ala-Ser-Leu-Glu-Met- 
Ser-Ala-Leu) was used as a competitive blocking agent for immu- 
noblots  and  immunocytochemistry.  R.abbit  antibody  to  pure 
mouse  NOS2  was  described (40).  Affinity-purified rabbit anti- 
bodies to synthetic peptides from rat NOS1  (amino acid residues 
1400-1419,  containing a single amino acid difference from hu- 
man NOS1) and human NOS3 (residues 1183-1202) were from 
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) and were used 
at 0.1  Ixg/ml. 
Specimens.  With  informed  consent,  bronchoalveolar lavage 
fluids were obtained for diagnostic purposes from 18 consecutive 
HIV-seronegative patients over 3  mo in  1995  in Hospital Uni- 
versitario Clementino  Fraga Filho (R.io  de Janeiro)  and 2  such 
patients at BeLlevue  Hospital (New York)  who  presented with 
clinical findings and roentgenographic evidence suggestive of ac- 
tive pulmonary tuberculosis and whose lavage specimens subse- 
quently proved culture-positive for M.  tuberculosis. 9  additional 
patients proved to have other diagnoses. Bronchoscopy specimens 
were also obtained from 11 healthy volunteers (2 from Rio de Ja- 
neiro and 9 from New York). Human study protocols were ap- 
proved by the institutional review boards. Of the 20 samples col- 
lected from patients with tuberculosis, 17 were stored for R.NA 
analysis. In 16 of these, R.T-PCR. demonstrated ~-actin mR.NA, 
which was taken as an indication that the samples were of suffi- 
cient quality for further study. 14 of the 20 samples were aliquot- 
ted  for  preparation  of Cytospin  |  slides  (Shandon  Instruments, 
Sewicky, PA), and of these, 11 sets were sufficient in number and 
quality to undergo  evaluation by immunocytochemistry and/or 
diaphorase activity. Samples from 7 of the 11  healthy volunteers 
were adequate for immunocytochemistry and/or diaphorase stud- 
ies.  Slides were fixed in cold acetone for 10 rain, air dried, and 
stored at -20 to -70~ 
As described (41),  human renal epithelial 293  cells (American 
Type Culture Collection, R.ockviLle, MD) were transiently trans- 
fected by  the  calcium phosphate  method  with  human  NOS2 
cDNA (42) (a gift of Dr. T. Billiar, University of Pittsburgh, PA) 
or human NOS1  (a gift of P.  Marsden, University of Toronto, 
Canada) (43) in the pcDNAI vector (Invitrogen, San Diego, CA), 
with the vector alone, or with a mouse-human NOS2 chimera in 
which  the  COOH-terminal  24  amino  acid residues of mouse 
NOS2 were replaced with the cognate 27 residues of the human 
enzyme (Q.-w. Xie, unpublished observation). Human umbilical 
vein endothelial cell monolayers were the kind gift of Dr.  Siu- 
kong Lo (Cornell University Medical College). Lysates of 109 M. 
tuberculosis bacilli strain H37R.a (gift of Drs. S. Ehrt and L. R.iley, 
Cornell  University  Medical  College)  were  immunoblotted  in 
parallel. Peritoneal macrophages were collected from  129/SvEv 
￿  C57BL/6  wild-type and homozygous NOS2-deficient mice 
(4) 24 h after intraperitoneal injection of 104 units pure, recombi- 
nant mouse interferon-~/ (Genentech, Inc., South San Francisco, 
CA)  and 5  ~g bacterial lipopolysaccharide (from Escherichia coli 
0111:B4; Sigma, St. Louis, MO). 
Immunoblotting.  Human  NOS2  is  susceptible  to  primary 
structural degradation when boiled in Laemmli's buffer (J. Calay- 
cay and Q.-w. Xie, unpublished observations). Accordingly, un- 
heated lysates were electrophoresed under denaturing, reducing 
conditions on  7.5%  polyacrylamide gels,  blotted to  Immobilon 
membranes  (Millipore Corp.,  Bedford,  MA),  and  probed with 
NO53 IgG at 4 ng/ml or its F(ab')2 fragment at 132 ng/ml. Bound 
rabbit Ig was detected with donkey anti-rabbit IgG conjugated with 
horseradish peroxidase (Amersham Corp., Arlington Heights, IL) as 
revealed by enhanced chemiluminescence (Du Pont, Boston, MA). 
(Immuno)Cytochemistry.  Slides were  blocked  for  60  rain  at 
room  temperature  (R.T)  in  10%  normal goat serum  (NGS)  in 
Tris-buffered saline (TBS), incubated for 60 rain in 4 ng/ml pre- 
immune IgG or NO53 IgG or 132 ng/ml of its F(ab')2 in NGS/ 
TBS  with  or  without  10  ~g/ml  of blocking peptide  NO54, 
washed three times (5 rain each)  in TBS, and then incubated 60 
rain in 1:500  dilution of goat IgG anti-rabbit IgG conjugated to 
biotin (Vector Labs.). After washing, the slides were incubated in 
avidin-conjugated alkaline phosphatase according to  the  manu- 
facturer's instructions (ABC Kit: Vector Labs.), washed thrice in 
TBS, and then incubated in Vector (Texas)  R.ed or Vector Blue 
substrate for "~20 nfin. Slides were coverslipped in 10% glycerol 
and percent positive cells scored among 500 cells per sample un- 
der direct illumination (4005<).  For illustrative purposes,  some 
slides developed with Vector R.ed were also photographed under 
epifluorescence with a Nikon B  excitation filter (bandpass,  460-- 
485  nm). With this filter, macrophage autofluorescence appeared 
yellow-green, allowing a clear distinction from positive staining 
(red). Emission intensity from Texas red under these conditions of 
excitation was expected to be only ,'-~13% of that for excitation at 
596 nm; nonetheless, the signal was brighter than by brightfield. 
Some specimens stained with preimmune IgG, and this reac- 
tivity was  not blocked by peptide NO54.  Staining with  these 
characteristics was deemed nonspecific. In an attempt to circum- 
vent nonspecific reactivity, we tried to affinity-purify NO53  on 
NO54 coupled to solid supports. However, the affinity of NO53 
for NO54 was so high that no antibody could be eluted (J. Calaycay 
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talized  on the high affinity of specific NO53-antigen interaction 
by applying an acid wash in situ  to disrupt  nonspecific interac- 
tions,  as follows. Slides from samples that showed staining by pre- 
immune serum as developed in Vector Blue were decolotized in 
xylene for 20 min. Slides developed in Vector Ked could not be 
decolorized; when available, fresh slides from such patients  were 
submitted  to  the  same  procedures.  The  air-dried  slides were 
blocked in 5% BSA,  100 ~g/ml goat "/-globulin in TBS  (BSA/ 
ggg) for 60 min, then incubated in preimmune IgG, NO53, or 
NO53 plus NO54 as above, the reagents  being diluted in BSA/ 
ggg. The samples were then incubated for 30 rain at 1KT in 50 
mM glycine buffer, pH 2.5, washed twice in TBS, and developed 
with the second antibody and avidin-alkaline  phosphatase  ABC 
reagents as above, using either Vector Red or Vector Blue as sub- 
strates.  As controls, slides that had been processed according to 
the standard  procedure and showed only specific  staining  were 
subjected to the alternative  procedure; they gave the same per- 
cent positive  ceils as before. Slides that showed nonspecific stain- 
ing according to the standard procedure showed no staining after 
the alternate  procedure. 
Other slides were stained by standard procedures using mono- 
clonal antibodies  to  CD3,  CD4,  or CD8  (Coulter  Corp.,  Hi- 
aleah, FL). 
To detect enzymatic activity,  companion slides were incubated 
in 50 mM Tris, pH 8, with 0.3 mM nitroblue tetrazolium  (Sigma), 
1 mM NADPH, 0.2% Triton X-100 for 30 rain at 370C, washed, 
mounted in glycerol, and scored as above under bright-field illu- 
mination. 
RT-PCR.  From 16 culture-positive tuberculosis  patients  and 
2 healthy volunteers each from Rio de Janeiro and New York, 
bronchoalveolar lavage  ceils were available that had been stored 
in 1KNA Stat-60 (Tel-Test B, Inc., Friendswood, TX) at -70~ 
Human 293 cells transfected  with NOS2 cDNA (42) or vector 
alone constituted positive  and negative controls. Total RNA (1 
Ixg) was  reverse-transcribed  using  oligo-d(T)~ 6 and  PC1K per- 
formed  by  standard  methods  (GeneAmp  system  9600;  Perkin 
Elmer).  First-round PC1K was carried out with 20% of the cDNA 
using oligonucleotide with primers from exon 1 (5'-CAC CTT 
TGA TGA GGG  GAC-3') and  exon 4  (5'-GCA TCC AGC 
TTG ACC AG-3') of human NOS2 (44). For nested PCR, 4% 
of the first-round product was amplified  with primers  from exon 
1  (5'-ATG AGG GGA CTG GGC AGT TC-3')  and  exon 4 
(5'-GCT TGA CCA GCG ATT CTG GAG-3'). After electro- 
phoresis  in  1.5% agarose,  reaction products (10  I~i) were trans- 
ferred to nylon membranes (Nytran-Plus; Schleicher & Schuell, 
Keene, NH) and autoradiographed after probing with 32p-labeled 
oligonucleotide derived from a sequence of NOS2 internal  to the 
primers  (5'-CCT  TAC  CCC  GGG  GAG  GCA  GTG  CAG 
CCA G'3'). 
Cloning and Sequencing of NOS2 R T-PCR Products.  Nested IKT- 
PC1K products from 3 patients and 1 healthy control were excised 
from the  electrophoretic  gel and purified  (Qiagen,  Chatworth, 
CA). The DNA was ligated  into the EcolKV site of the pT7Blue 
vector containing the lacZ ot-peptide  (Novagen, Madison, WI) 
and transformed into E. coli NovaBlue competent cells, express- 
ing the LacZ-r  fragment. Transformed cells were grown on LB 
agar containing ampicillin,  X-gal and isopropyl ~-D-thiogalacto- 
pyranoside.  Five clones from each transformant were selected and 
the presence of the cloned DNA fragment confirmed by restric- 
tion with BamHI and Sail. At least one clone from each transfor- 
mant was sequenced (373 DBA sequencer; Applied Biosystems, 
Foster City, CA). 
Results 
Characterization of Anti-NOS2 Antibody.  Antibody NO53 
was raised against a synthetic pepfde that contains the ex- 
treme  COOH-terminal  heptamer  of human NOS2,  a  se- 
quence not represented elsewhere in the currently available 
protein data base. In particular, this sequence is absent from 
human  NOS1,  human  NOS3,  and  mouse  NOS2.  Anti- 
body NO53 reacted with peptide  NO54 in ELISA with a 
titer of 1:400,000 (not shown). When 293 cells were trans- 
fected with human NOS2 cDNA, NO53 immunoblotted a 
single polypeptide  species  whose  apparent  molecular mass 
('-d33 kD) corresponded to that of the NOS2 monomer. 
Immunoreactivity was abolished by a molar excess of pep- 
tide NO54, and was absent using preimmune IgG from the 
same rabbit  (Fig.  1).  Immunocytochemistry confirmed the 
reactivity of NO53 with 293  cells  transfected with human 
NOS2,  and not those  transfected with vector alone.  That 
the  epitope  recognized by NO53  was  represented  in  the 
COOH  terminus  of human  NOS2  was  demonstrated by 
the  ability  of NO53  to  immunoblot  293  cells  transfected 
with  a  chimeric  construct in which the  COOH  terminus 
of mouse NOS2 was replaced with the  corresponding re- 
gion from human NOS2 (Fig.  1). In contrast, NO53 could 
not react with full-length mouse NOS2. Expression of the 
latter was confirmed by its reactivity with anti-mouse NOS2 
antibody (Fig. 1). 
When  293  cells  were  transfected  with  human  NOS1 
cDNA,  they  remained  NO53-negative  by  immunoblot 
and immunofluorescence.  Similarly, lysates of human um- 
bilical vein endothelial  cells  (HUVEC) were not immuno- 
blotted by NO53. NOSl-transfected 293 cells were immu- 
noblot-positive  with  anti-NOS1  antibody,  and  HUVEC 
were immunoblot-positive with anti-NOS3 antibody, prov- 
ing the presence of the isoforms with which NO53 did not 
react (Fig. 1). 
Because  Freund's  complete  adjuvant  was  used  to  raise 
NO53,  it was necessary to exclude the possibility that the 
antibody  might  also  react  with  mycobacterial  antigens. 
NO53 did not immunoblot a lysate prepared from 109 ba- 
cilli  of M.  tuberculosis H371La  (the  strain  used  in  Freund's 
complete adjuvant) (Fig. 1). Moreover, when human mono- 
cytes were productively infected with M. tuberculosis H371Ka, 
they remained  nonreactive  with  NO53  (Almeida,  G.,  H. 
Cho, C. Nathan and J. Ho, unpublished observations). 
Thus, NO53 appeared to react with a COOH-terminal 
epitope of human NOS2, but not with mouse NOS2,  hu- 
man NOS1, human NOS3, any other proteins in a human 
epithelial  cell line,  other proteins  in human macrophages, 
or mycobacterial antigens  expressed in broth culture  or in 
macrophages. 
Immunoreactivity  of Macrophages from  Patients with Tubercu- 
losis.  NO53 stained macrophages from the lungs of 11  of 
11  patients presenting with untreated,  culture-positive  tu- 
berculosis (8 males, 3 females; mean age 39 yr, range 20-74 
yr)  (Figs.  2,  3).  For  all  11  tuberculosis  patients,  NO53 
stained  49  -+  20%  (mean  +-  SD)  of their bronchoalveolar 
lavage cells  (range 25-80%). Lymphocytes comprised 14 + 
2295  Nicholson et al. Figure 1.  Characterization  of antibody NO53 by immunoblot. As summarized in the inset, whole cell lysates of 293 cells (30 I.tg  protein/lane) trans- 
fected with vector alone (lanes l), with mouse NOS2 (lanes 2), with chimeric NOS2 consisting of mouse NOS2 bearing the COOH-terminal 24 resi- 
dues from human NOS2 (lanes 3), with human NOS2 (lanes 4); or with human NOS1 (lanes 6); HUVEC (7 ￿  105 cells/lane; lanes 5); or M. tuberculosis 
(108 organisms/lane; lane 7) were electrophoresed in 7.5% SDS-PAGE, then transferred to Immobilon membranes. The membranes were blotted with 
(a) NO53 IgG, (b) NO53 +  NO54 blocking peptide, (c) rabbit anti-mouse holo-NOS2 IgG, (d) rabbit IgG against human NOS3-derived peptide; (e) 
rabbit IgG against human NOSl-derived peptide, or (f) preimmune IgG from the rabbit in which NO53 was raised. The faint smudge in a, lane 6 does 
not correspond to the molecular mass of  human NOS1 monomer (160 kD). 
3% of the total cell population as assessed  by expression of 
CD3  or the combination of CD4  +  CD8  (whichever was 
greater),  whereas  10  •  4% of the cells were polymorpho- 
nuclear leukocytes and 0.9  •  0.3%  were  scored morpho- 
logically as epithelial cells.  The rest of the lavage cells (75  • 
5%)  and  100  •  0%  of the  NO53-positive  cells  had mor- 
phologic characteristics  of macrophages  (Figs.  2,  3).  Thus, 
on average, 65% of the macrophages were NOS2-positive. 
Results  were  no  higher  for  the  subset  of subjects  who 
smoked  tobacco  (39  •  15%  of lavage  cells;  n  =  6)  than 
those who did not (60  +  15% oflavage cells;  n  =  4);  the 
smoking status of one subject was unknown. 
In lavage specimens from 5 nonsmoking normal donors, 
10  •  5%  of the  cells  (almost  all  of which  were  macro- 
phages) stained with NO53  (range 2-16%)  (Fig. 2).  In two 
clinically normal  donors who smoked,  24 and 62%  of the 
cells  were NO53-positive. 
Diaphorase  Cytochemistry.  Only  small  numbers  of cells 
could be diverted from the diagnostic studies for which the 
bronchoscopies were carried out, and these were promptly 
fixed for transport.  These  constraints precluded  any direct 
measurement of NO  production by explanted  cells.  How- 
ever, mouse NOS2 in fixed sections can reduce tetrazolium 
salts  (45,  46).  Consistent  with  this,  293  cells  became  dia- 
phorase-positive after transfection with NOS2 cDNA (Fig. 
4).  With  live  cells,  diaphorase  activity can  also  reflect  su- 
peroxide produced by the respiratory burst oxidase (47), an 
enzyme system present in human pulmonary alveolar mac- 
rophages (48). However, peritoneal macrophages that were 
activated in vivo and then collected and fixed were diapho- 
rase-negative  when  they  derived  from  NOS2-deficient 
mice,  whereas  those  from  NOS2-replete  mice  were  dia- 
phorase-positive (Fig. 4),  even though the respiratory burst 
is  normal  in  macrophages  from the  NOS2-deficient  mice 
(4).  Thus, as applied herein to fixed cells,  the diaphorase as- 
say strictly depended on expression of NOS2. 
The proportion of tuberculosis patients' bronchoalveolar 
lavage cells that were positive by diaphorase  cytochemistry 
(45  "+- 27%, 9 subjects)  (Fig. 3) closely matched the propor- 
tion positive for NO53 reactivity (49  •  20%). 
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cal  detection  of NOS2  in  pul- 
monary  alveolar  macrophages 
from a patient with tuberculosis 
but  not  in  cells  from  a  normal 
donor:  bright'field studies.  Cells 
were  freshly  isolated  by  bron- 
choalveolar  lavage  from  (a-c)  a 
patient with tuberculosis or (d) a 
non-smoking  normal  donor, 
and stained with (a)  preimmune 
IgG or (b-d) NO53 IgG, with (c) 
or  without  (b  and  d)  blocking 
peptide  NO54.  (a-c)  Stained 
with Vector Red; original ￿ 
(d)  Stained  with  Vector  Blue; 
original X200. 
Figure  3.  Immunocytochemi- 
cal  detection  of NOS2  in  pul- 
monary  alveolar  macrophages 
from  three  additional  patients 
with  tuberculosis:  immunofluo- 
rescence. Cells were freshly iso- 
lated  by  bronchoalveolar  lavage 
and stained with  (a)  preimmune 
IgG or (b-d) NO53 IgG. Results 
with  NO53  IgG  plus  blocking 
peptide  resembled  those  in  (a) 
and are not shown.  (a-c)  Origi- 
nals  X400;  (d) original ￿  (a 
and b) Cells are from one patient; 
(c and d) two additional patients. 
Under  a  460-485-nm  bandpass 
excitation filter, positive cells flu- 
oresce red and negative cells au- 
tofluoresce yellow-green. 
2297  Nicholson et al. Figure 4.  Diaphorase  histochemistry. (a and b) 293 cells were transfected (a) with human NOS2 cDNA or (b) vector alone. Activated  mouse peritoneal 
macrophages were collected  from (c) wild-type or (d) NOS2-deficient mice. Bronchoalveolar  lavage cells were collected from (e) a non-smoking, healthy 
volunteer and (f) a patient with tuberculosis. (a-d) Originals ￿  (e and  f) originals ￿ 
Detection of NOS2 mRNA.  RT-PCR  provided evidence 
for the presence of NOS2 independent of antibody. Of the 
16  tuberculosis  patients'  samples  tested,  12  supported  the 
amplification from NOS2-specific primers of a product that 
hybridized with  a  NOS2--specific probe encoded between 
but not within the regions of the NOS2 gene used for de- 
signing the primers.  Visualization  of this product was evi- 
dent  after first-round  PCR  in 7  cases and required  nested 
PCR  in the remaining 5. The NOS2-hybridizing product 
was of the expected size (413 bp)  in 9  of the  12 cases  (Fig. 
5, A  and B).  In the  other 3  patient  samples,  the amplified 
product was larger ("-~500 bp; not shown). In none of the 4 
2298  Nitric Oxide Synthase in Human Macrophages Figure  5.  Detection of NOS2 mRNA. All PCR. reactions illustrated 
were nested, and detection was by means of Southern hybridization to an 
internal NOS2-specfic probe. Positive control reactions illustrated were 
direct PCP, amplification of NOS2 cDNA itself (/t, lane 1), and RT- 
PCR of 293 cells transfected with NOS2 cDNA (/t, lane 2; B, lane 1). 
Negative control reactions illustrated were lkT-PCR of human periph- 
eral blood monocyte=derived  macrophages (B, lane 8), and RT-PCP, in 
the absence of a template (A, lane 8). Experimental results were from 
RT-PCR of  bronchoalveolar  lavage samples  from 13 tuberculosis patients 
(A, lanes 3-7, 9--I3; B, lanes 2-4) and from 3 healthy volunteers (B, lanes 
5-7). 
healthy  volunteers'  samples  tested  did  first-round  PCR 
yield  a  NOS2-specific  product.  However,  nested  PCI< 
yielded a 413-bp, NOS2-hybridizing product in 2  samples 
from normal donors (Fig.  5 B) and a "400 bp product in a 
third;  the  fourth  remained negative by nested PCR.  As a 
control, 293 cells were transfected with NOS2 cDNA; ap- 
plication  of nested  RT-PCR  demonstrated  the  expected 
413-bp product  (Fig.  5  A,  lane  2;  B,  lane  1)  comigrating 
with that produced by direct PCt< on NOS2  cDNA (Fig, 
5 A, lane  1). 
Cloning and sequencing of amplification products of the 
413-bp  products from one patient and one normal donor 
confirmed their identity as NOS2.  The larger amplificand 
was  also  cloned  and  sequenced  from two  patients.  From 
the 5' end, the first "o110 bp were identical to NOS2 exon 
1  and  its  junction  with  intron  1.  The  3'  end  closely 
matched the exon 4 primer used in PCR, while the inter- 
vening portion  was  of indeterminate  origin.  These  larger 
amplificands were  considered artefacts,  and  samples yield- 
ing them were scored as negative. 
Correlation of Results from Three Assays  for NOS2.  Sam- 
ples from 12 tuberculosis patients and 4 healthy volunteers 
were  sufficient for testing by 2  or more  of the  assays for 
NOS2  (immunocytochemistry,  diaphorase  cytochemistry, 
and IkT-PCI<). For the patients, 2 of 2 samples were posi- 
tive by all 3 assays, 8  of 10 by each of 2  assays, and the re- 
maining 2 by 1 of 2 assays. In contrast, samples from none 
of the 4 healthy volunteers tested by 2 assays were positive 
by both. 
Discussion 
Many studies  of NOS2  expression in human  cells  have 
been clouded by lack of evidence for the specificity of the 
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antibodies  used  or by their  subsequently  revealed lack  of 
specificity. For example, a mAb reactive with mouse NOS2 
and widely used as an anti-human NOS2  reagent was re- 
cently shown to bind human NOS1  (49).  To our knowl- 
edge, the present report provides the first documentation of 
the  monospecificity of an antibody against human NOS2, 
and  the  first evidence for expression  of NOS2  protein in 
human mononuclear phagocytes using such an antibody. 
Inducible  NOS  was detected  in  a  mean of 65%  of the 
pulmonary  alveolar macrophages  of 100%  of 11  patients 
with  newly  diagnosed,  untreated  pulmonary tuberculosis. 
In contrast,  in  5  normal subjects,  NOS2-positive  alveolar 
ceils  averaged 10%  of the  bronchoalveolar lavage popula- 
tion. In two clinically normal smokers, NOS2-positive cells 
were  much more frequent  (mean 43%).  Likewise,  exten- 
sive NOS2  reactivity was evident in alveolar macrophages 
from patients with a variety of other pulmonary inflamma- 
tory disorders,  such  as  nontuberculous  pneumonia  (52  + 
9% of alveolar lavage cells;  n  =  5),  cancer (24 +  24%; n  = 
2),  sarcoidosis  (20%;  n  =  1)  (Bonecini-Almeida,  M.G.,  S. 
Nicholson, J.B,. Lapa e Silva, C. Nathan, and J.L. Ho, un- 
published observations), and nocardiosis (90%;  n =  1; Cho, 
H., W.  R.om,  and  C.  Nathan,  unpublished  observations). 
Smoking  cannot  account  for all  of the  results  in  patients 
with tuberculosis, since at least 4  of the  11  did not smoke, 
and the NO53-positivity ofmacrophages in this subset was 
if anything more extensive than among the  smokers. The 
substantially greater degree of NOS2 expression in alveolar 
macrophages  of tubercular  compared  to  normal  subjects 
may signify that NOS2 was induced in the patients' alveo- 
lar macrophages by cytokines and/or mycobacterial prod- 
ucts (50). 
First-round  R.T-PCR  was  positive  for  NOS2  with  7 
samples from 16 tuberculosis patients but not with samples 
from the 4 normals. The latter results are consistent with a 
recent study in which first-round P,T-PCP,  was negative 
for NOS2 when applied to pulmonary alveolar macrophages 
from 4 normal subjects (51).  In the present work, however, 
nested PCP,. with Southern blot detection was positive in 2 
of 4 normal subjects' samples, consistent with the presence 
of a few NOS2-positive cells by immunocytochemistry. The 
difference between the present work and the study of Guo 
et al.  (51)  with respect to an occasional minor representa- 
tion versus a complete lack of NOS2-positive macrophages 
in normal subjects might be attributable to the presence of 
subclinical pulmonary inflammation in some of our volun- 
teers and/or to differences in assay sensitivity. 
Circumstances  have  been  described  with  human  (21) 
and mouse (52)  macrophages in which NOS2 protein was 
detectable but little  or no NO  was generated.  To test for 
enzymatic activity in fixed preparations of NOS2-positive 
cells,  we used diaphorase cytochemistry. Under the condi- 
tions tested, expression of NOS2 was strictly required for a 
positive  reaction.  The  proportion  of diaphorase-positive 
pulmonary lavage cells  from tuberculous  patients matched 
that of NOS2-positive cells.  There is no precedent for ex- 
pression of a NOS that preserves diaphorase activity but has 
lost the ability to produce NO. Thus, the expression of di- aphorase activity is strong evidence for the presence of the 
high-output NO pathway before fixation. 
When  present  in  human  macrophages  in  vitro,  NOS2 
appears to contribute to their antimicrobial activity against 
Mycobacterium avium (16),  Trypanosoma  cruzi (I8), and Leish- 
mania  major  (32).  While  there  are  apparently  no  such  re- 
ports for M.  tuberculosis, human macrophages do not appear 
to have been infected in vitro with the latter organism un- 
der conditions in which they abundantly expressed NOS2, 
and thus the experimental conditions seem not to have ad- 
equately reproduced the milieu of the infected lung. Given 
that NOS activity appears to be essential for the control of 
tuberculous  infection  in  mice  (6-8),  the  present  findings 
suggest that NOS2 may constitute an element  of the anti- 
mycobacterial  armamentarium  of human  macrophages  in 
vivo. 
These  findings  bring  new  questions  to  the  fore.  What 
host  and mycobacterial products  augment  or suppress  the 
expression of NOS2 in tuberculosis? Are there any NOS2- 
positive cells in the lungs of patients with tuberculosis cells 
besides  the macrophages recovered by lavage, such as epi- 
thelial cells (51, 53), and if so, do they contribute to control 
of the infection, considering that NOS2 can exert trans-cel- 
lular  anti-viral  effects  (2,  54)?  Are  the  consequences  of 
NOS2 expression predominantly beneficial, such as tuber- 
culostasis  (55),  or potentially harmful,  such as lymphostasis 
(56),  epithelial  destruction  (53,  57)  or cavitation?  What is 
the  impact of endogenous  NO  on pulmonary ventilation 
and perfusion in tuberculosis (58)? Might persistent expres- 
sion of NOS2 within  the  granuloma help  maintain  tuber- 
cular dormancy? Is reactivation of disease associated with a 
lapse in NOS2 expression by the host, or a loss of suscepti- 
bility to NO on the part of the pathogen? 
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